---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-078116"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T12:50:09.008476+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BrainStorm Q2 net loss $2.9M; FDA clears Phase 3b NurOwn trial

## Summary
- Cash and equivalents total $1.03M as of June 30, 2025.
- Net loss per share improved to $0.34 from $0.60 YoY.
- G&A expenses fell to $1.4M from $2.1M; R&D rose to $1.1M from $0.9M.
- FDA cleared Phase 3b ENDURANCE trial targeting ~200 ALS patients.
- Signed LOI with CDMO Minaris for NurOwn manufacturing for the trial.

## SEC filing metadata
- accession: 0001104659-25-078116
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465925078116/0001104659-25-078116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465925078116/tm2523508d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-078116
- JSON: https://secwatch.observer/filing/0001104659-25-078116.json
- Plain text: https://secwatch.observer/filing/0001104659-25-078116.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.